Download PDF
Synlett 2023; 34(02): 159-162
DOI: 10.1055/a-1968-2684
letter

Synthesis of (S)-Nyasol through a Copper-Catalyzed Propargylic Substitution

Yuichi Kobayashi∗
,
Takayuki Hirotsu
This work was supported by JSPS KAKENHI Grant Number 20K05501.
› Further Information
    Permissions and Reprints All articles of this category


Abstract

(S)-Nyasol was selected as a target to demonstrate the efficiency of a copper-catalyzed substitution of secondary propargylic phosphates. The key phosphate (R)-TBDPSO(CH2)2CH[C≡C(C6H4-4-OTBS)]OP(O)(OEt)2 was synthesized from TBDPSO(CH2)2CO2H in four steps. Substitution of the phosphate with 4-TBSOC6H4MgBr in the presence of CuBr·Me2S as a catalyst in THF–DME proceeded with both stereo- and regioselectivity at the propargylic position. All the silyl groups in the propargylic product, TBDPSO(CH2)2CH[C≡C(C6H4-4-OTBS)](C6H4-4-OTBS) were removed, and the acetylene bond was reduced by using active Zn to produce the cis-olefin. Finally, the HO(CH2)2 moiety was converted into CH2=CH, giving (S)-nyasol with 97% cis selectivity, 94.5% ee, and >99% enantiospecificity. Similarly, dihydronyasol was synthesized through hydrogenation of the substitution product, followed by construction of the terminal olefin.

Key words

synthesis - nyasol - propargylic substitution - phosphates - copper catalysis - Grignard reagents

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/a-1968-2684.
  • Supporting Information


Publication History

Received: 25 September 2022

Accepted after revision: 26 October 2022

Accepted Manuscript online:
26 October 2022

Article published online:
25 November 2022

© 2022. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References and Notes

  • 1 Present address: Meiji University, Organization for the Strategic Coordination of Research and Intellectual Properties, 1-1-1 Higashimita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan.
  • 2 Kobayashi Y, Takashima Y, Motoyama Y, Isogawa Y, Katagiri K, Tsuboi A, Ogawa N. Chem. Eur. J. 2021; 27: 3779
    CrossrefPubMed
  • 3 Takashima Y, Isogawa Y, Tsuboi A, Ogawa N, Kobayashi Y. Org. Biomol. Chem. 2021; 19: 9906
    CrossrefPubMed
  • 4 Ogawa N, Uematsu C, Kobayashi Y. Synlett 2021; 32: 2071
    Article in Thieme Connect
    • 5a Akiyama K, Gao F, Hoveyda AH. Angew. Chem. Int. Ed. 2010; 49: 419
      CrossrefPubMed
    • 5b Hamilton JY, Sarlah D, Carreira EM. J. Am. Chem. Soc. 2013; 135: 994
      CrossrefPubMed
    • 5c Gao F, Carr JL, Hoveyda AH. J. Am. Chem. Soc. 2014; 136: 2149
      CrossrefPubMed
    • 6a Fang Y, Park H. Synth. Commun. 2015; 45: 137
      Crossref
    • 6b Kwon J, Kondaji G, Song S, Kim C, Lee K, Kim W.-K, Choi Y. Bull. Korean Chem. Soc. 2013; 34: 1247
      Crossref
    • 7a Oketch-Rabah HA, Dossaji SF, Christensen SB, Frydenvang K, Lemmich E, Cornett C, Olsen CE, Chen M, Kharazmi A, Theander T. J. Nat. Prod. 1997; 60: 1017
      CrossrefPubMed
    • 7b Lassen PR, Skytte DM, Hemmingsen L, Nielsen SF, Freedman TB, Nafie LA, Christensen SB. J. Nat. Prod. 2005; 68: 1603
      CrossrefPubMed
  • 8 Tsui W.-Y, Brown GD. Phytochemistry 1996; 43: 1413
    CrossrefPubMed
  • 9 Iida Y, Oh K.-B, Saito M, Matsuoka H, Kurata H, Natsume M, Abe H. J. Agric. Food Chem. 1999; 47: 584
    CrossrefPubMed
  • 10 Marini-Bettolo GB, Nicoletti M, Messana I, Galeffi C, Msonthi JD, Chapya WA. Tetrahedron 1985; 41: 665
    CrossrefPubMed
  • 11 Minami E, Taki M, Takaishi S, Iijima Y, Tsutsumi S, Akiyama T. Chem. Pharm. Bull. 2000; 48: 389
    CrossrefPubMed
  • 12 Song M.-C, Yang H.-J, Bang M.-H, Kim D.-K, Jeong T.-S, Kim J.-P, Baek N.-I. Arch. Pharmacal Res. 2007; 30: 1392
    CrossrefPubMed
  • 13 Jeong S.-J, Higuchi R, Ono M, Kuwano M, Kim Y.-C, Miyamoto T. Biol. Pharm. Bull. 2003; 26: 1721
    CrossrefPubMed
    • 14a Suzuki S, Nakatsubo T, Umezawa T, Shimada M. Chem. Commun. 2002; 1088
      CrossrefPubMed
    • 14b Suzuki S, Yamamura M, Shimada M, Umezawa T. Chem. Commun. 2004; 2838
      CrossrefPubMed
    • 15a Xu Y, Salman M, Khan S, Zhang J, Khan A. J. Org. Chem. 2020; 85: 11501
      CrossrefPubMed
    • 15b Ameer F, Drewes SE, Drewes MW, Roos GH. P, Watson MC. J. Chem. Soc., Perkin Trans. 1 1988; 1425
      Crossref
    • 15c Paez Beracierta A, Whiting DA. Tetrahedron Lett. 1976; 2367
      Crossref
  • 17 Carlsen PH. J, Katsuki T, Martin VS, Sharpless KB. J. Org. Chem. 1981; 46: 3936
    CrossrefPubMed
  • 18 Matsumura K, Hashiguchi S, Ikariya T, Noyori R. J. Am. Chem. Soc. 1997; 119: 8738
    CrossrefPubMed
  • 19 4,4′-[(3R)-5-Hydroxypent-1-yne-1,3-diyl]diphenol (11) A 0.71 M solution of Grignard reagent 5 in THF (13.0 mL, 9.23 mmol) was added to an ice-cold solution of CuBr·Me2S (236 mg, 0.901 mmol) in THF (12 mL) and DME (12 mL). After 30 min at 0 °C, a solution of phosphate 4 (2.44 g, 3.58 mmol) in THF (48 mL) was added, and the mixture was stirred at 0 °C for 1 h, then poured into sat. aq NH4Cl. The resulting mixture was extracted with EtOAc (×3), and the crude product was passed through a short column of silica gel with hexane–EtOAc (50:1 to 30:1) to afford semipurified alkyne 3, which was used for the next reaction without further purification. The reaction was repeated with phosphate 4 (415 mg, 0.609 mmol), a 0.75 M solution of reagent 5 in THF (2.03 mL), and CuBr·Me2S (31 mg, 0.151 mmol) in THF (total 10 mL) and DME (2 mL) to give 3 as a slightly yellow liquid; yield: 313 mg (70%, 95.2% ee); Rf = 0.52 (hexane–EtOAc, 20:1); HPLC [Chiralcel OD-H, hexane–i-PrOH (99.9:0.1), 0.3 mL/min, rt]: t R = 59.6 (R-isomer, major), 73.9 min (S-isomer, minor); >99% regioselectivity by integration of the diagnostic 1H NMR signals for 3 [δ = 4.13 (t, J = 7.5 Hz, 1 H)], allene 13 (for synthesis, see Supplementary Information) [δ = 5.68 (t, J = 6.8 Hz, 1 H)], and alkyne 3 [1H NMR (300 MHz, CDCl3): δ = 0.19 (s, 12 H), 0.98 (s, 9 H), 0.99 (s, 9 H), 1.07 (s, 9 H), 1.92–2.10 (m, 2 H), 3.72 (dt, J = 10.4, 5.2 Hz, 1 H), 3.92 (dt, J = 10.4, 6.5 Hz, 1 H), 4.13 (t, J = 7.4 Hz, 1 H), 6.72–6.82 (m, 4 H), 7.22–7.46 (m, 10 H), 7.66–7.75 (m, 4 H)]. A solution of semipurified alkyne 3 in THF (36 mL) was treated with a 1.0 M solution of Bu4NF in THF (72 mL, 72 mmol). After the addition, the yellow solution turned blue, and the mixture was stirred at rt for 4 h, then diluted with sat. aq NH4Cl. The mixture was repeatedly extracted with EtOAc, and the crude product was purified by chromatography [silica gel, hexane–EtOAc (2:1 to 1:2)] to give phenol 11 as a slightly yellow liquid; yield: 602 mg (63% over two steps): Rf = 0.15 (hexane/EtOAc = 1:1). IR (neat) 3348, 2188, 1704, 1608, 1511, 1240, 832 cm–1. 1H NMR (300 MHz, CD3OD): δ = 1.88–2.02 (m, 2 H), 3.64 (dt, J = 10.9, 6.0 Hz, 1 H), 3.77 (dt, J = 10.9, 6.9 Hz, 1 H), 3.91 (t, J = 7.3 Hz, 1 H), 6.71 (dm, J = 8.7 Hz, 2 H), 6.75 (dm, J = 8.7 Hz, 2 H), 7.23 (dm, J = 8.7 Hz, 4 H). 13C–APT NMR (75 MHz, CD3OD): δ = 34.9 (+), 42.8 (–), 60.7 (–), 84.1 (–), 90.0 (–), 115.9 (–), 116.2 (+), 116.3 (+), 129.4 (+), 133.9 (+), 134.3 (–), 157.2 (–), 158.5 (–). HRMS (FAB): m/z [M + H]+ calcd for C17H17O3: 269.1178; found: 269.1180.Note that phenol 11 is marginally soluble in CDCl3.
  • 20 The over-reduction product 14 was synthesized by hydrogenation with 10% Pd/C.
    • 21a Aerssens MH. P. J, van der Heiden R, Heus M, Brandsma L. Synth. Commun. 1990; 20: 3421
      Crossref
    • 21b Wang Y.-G, Takeyama R, Kobayashi Y. Angew. Chem. Int. Ed. 2006; 45: 3320
      CrossrefPubMed
  • 22 Grieco PA, Gilman S, Nishizawa M. J. Org. Chem. 1976; 41: 1485
    Crossref